Compare Novavax Inc (NVAX) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Skyworks Solutions Inc — how do they compare? Novavax Inc trades at $8.12 (market cap $1.30B), while Skyworks Solutions Inc trades at $62.97 (market cap $8.99B). The key difference: Skyworks Solutions Inc is far larger — about 6.9× Novavax Inc's market cap, and Skyworks Solutions Inc pays a 4.75% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | SWKS | |
|---|---|---|
Market Cap | $1.30B | $8.99B |
Sector | Health | Technology |
52-Week High | $11.19 | $83.40 |
52-Week Low | $6.22 | $52.50 |
Enterprise Value | $800.50M | $8.76B |
Dividend Yield | — | 4.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
Skyworks Solutions (SWKS) trades at $62.95, up 6.14% on the day, with a bearish technical signal but strong fundamental valuation metrics including a P/E of 24.91 and P/S of 2.22. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Recent news highlights ongoing investigations into corporate governance alongside positive coverage of its EV and AI semiconductor innovations.
The stock presents a mixed outlook: analyst consensus is bullish with a $75.88 price target (35 Buy, 23 Hold, 2 Sell), but risks include declining revenue trends (2025: $4.09B, 2026 est: $4.0B), margin compression, and legal scrutiny. Near-term catalysts depend on Q2 earnings beat potential and EV/AI segment growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
